|
| Species | Tumor | Model | Immunologic effect | References |
|
| Human | HCC () | | HSP-70, HSP-90 (cytoplasm, membrane)↑ | [62] |
| HCC () | | Activation of myeloid dendritic cells (blood) | [51] |
| | | IL-1β, TNF (serum)↑ | |
| HCC () | | CD4+ and CD8+ cells (blood)↑ | [70] |
| | | CD3-CD56+, CD56+CD16+ cells (blood)↑ | |
| | | Activity of tumor-specific T cells↑ | |
| HCC () | | CD3-CD cells (blood)↑ | [67] |
| | | Activity of CD3-CD cells↑ | |
| HCC () | | Tumor-antigen specific T cells (blood)↑ | [77] |
| RCC () | | CD3+HLA-DR+, CD4+ and CD8+ cells (blood)↑ | [71] |
| | | CD56+CD16+cells (blood)↓ | |
| Liver metastases () | | Neutrophils (blood)↑ | [66] |
| HCC () | | | |
| Liver metastases () | | CD4+ and CD8+ cells (blood)↑ | [76] |
| HCC () | | | |
| Liver metastases of CRC | | IL-6 (serum)↑ | [52] |
| () | | | |
| Liver metastases () | | IL-6 (serum)↑ | [53] |
| HCC () | | | |
| Liver metastases () | | CD4+ cells (blood)↓ | [75] |
| HCC () | | MUC-1 specific T cells (blood)↑ | |
| | | B cells (blood)↑ (only in metastatic cancer patients) | |
| | | Trafficking of CD62L+ T cells into tissues | |
| Lung metastases () | | IL-8, MIP-1α, MIP-1β (serum)↑ | [54] |
| NSCLC () | | IL-10 (serum)↑ | |
| | | CD4+CD25+Foxp3+ cells (blood)↓ | |
| | | Neutrophils (blood)↑ | |
| Liver metastases () | | IL-6 (serum)↑ | [133] |
| HCC () | | IL-10 (serum)↑ | |
| Metastases () | ± chemotherapy | CD4+ and CD8+ responses against tumor-specific | [78] |
| Primary tumors () | | antigens (blood)↑ | |
| Metastases () | | Tumor-specific antibodies (serum)↑ | |
| HCC () | | HSP-70 (serum)↑ | [63] |
| RCC () | | | |
|
| Mouse | CRC | CT26 hEpCam ± huKS-IL2 | Antitumor activity (splenocytes)↑ | [74] |
| (BALB/c) | | | Tumor growth (distant tumor)↓ | |
| | | Tumor growth (rechallenge)↓ | |
| | C26 | CD4+ cells (perinecrotic)↑ | [65] |
| | | Neutrophils (perinecrotic)↑ | |
| | | Neutrophils and lymphocytes (distant metastases)↑ | |
| HCC | BNL ± CCL3 | CD11c+ cells (blood)↑ | [73] |
| | | CD11c+ cells (tumor)↑ | |
| | | CD4+ and CD8+ cells (tumor)↑ | |
| | | Tumor-specific cells (tumor)↑ | |
| | | Tumor growth (distant tumor)↓ | |
| | | Tumor growth (rechallenge)↓ | |
|
| Mouse | Melanoma | B16-OVA ± CTLA4-mAb | CD8+ tumor-antigen specific T cells (blood)↑ | [72] |
| (C57BL/6) | | ± Treg depletion | Tumor growth (rechallenge)↓ | |
| | B16-OVA ± CTLA4-mAb | Antigen loaded DC, DC maturation (draining | [69] |
| | | lymphnodes)↑ | |
| | | Tumor growth (rechallenge)↓ | |
| | B16-OVA ± DC | HSP-70, gp96 (tumor)↑ | [57] |
| | | HMGB1 (tumor)↑ | |
| | | CD8+ tumor-specific T cells (spleen, draining | |
| | | lymph nodes)↑ | |
| | | Local recurrence↓ | |
| | | Tumor growth (rechallenge)↓ | |
| Urothelial carcinoma | MB49 ± DC | CD4+, CD8+ antitumor responses (splenocytes)↑ | [49] |
| | | CD11c+cells (tumor)↑ | |
| | | Tumor growth (rechallenge)↓ | |
|
| Mouse | CRC | HT29 | HSP-70 mRNA (cytoplasm)↑ | [56] |
| (NIH (S)-nu) | | | | |
|
| Rabbit | Hepatoma | VX2 | Lymphocytes, plasma cells, and neutrophils | [68] |
| | | (tumor)↑ | |
| | | Tumor-specific T cells (blood)↑ | |
|
| Rat (Fisher) | Mammary | MatBIII | CD161+ cells (tumor-surrounding tissue)↑ | [61] |
| | | HSP-70 (tumor-surrounding tissue)↑ | |
| | R3230 ± liposomal | HSP-70 (around central coagulation zone)↑ | [59] |
| | doxorubicin | | |
|
| Rat (rNU) | Hepatoma | SK-HEP-1 | HSP-70, HSP-90 (cytoplasm, membrane)↑ | [55] |
|
